Skip to content

Advertisement

You're viewing the new version of our site. Please leave us feedback.

Learn more

BMC Medical Genetics

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Variants in CXCR4 associate with juvenile idiopathic arthritis susceptibility

  • Terri H. Finkel1, 2, 18Email author,
  • Jin Li3,
  • Zhi Wei4,
  • Wei Wang4,
  • Haitao Zhang3,
  • Edward M. Behrens1, 2,
  • Emma L. Reuschel1, 2,
  • Sophie Limou5,
  • Carol Wise6,
  • Marilynn Punaro7,
  • Mara L. Becker8,
  • Jane E. Munro9, 10,
  • Berit Flatø11,
  • Øystein Førre11,
  • Susan D. Thompson12,
  • Carl D. Langefeld13,
  • David N. Glass12,
  • Joseph T. Glessner3,
  • Cecilia E. Kim3,
  • Edward Frackelton3,
  • Debra K. Shivers1,
  • Kelly A. Thomas3,
  • Rosetta M. Chiavacci3,
  • Cuiping Hou3,
  • Kexiang Xu3,
  • James Snyder3,
  • Haijun Qiu3,
  • Frank Mentch3,
  • Kai Wang3, 14,
  • Cheryl A. Winkler5,
  • Benedicte A. Lie15,
  • Justine A. Ellis9, 16 and
  • Hakon Hakonarson2, 3, 17Email author
Contributed equally
BMC Medical GeneticsBMC series – open, inclusive and trusted201617:24

https://doi.org/10.1186/s12881-016-0285-3

Received: 20 August 2014

Accepted: 4 March 2016

Published: 22 March 2016

Abstract

Background

Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease among children, the etiology of which involves a strong genetic component, but much of the underlying genetic determinants still remain unknown. Our aim was to identify novel genetic variants that predispose to JIA.

Methods

We performed a genome-wide association study (GWAS) and replication in a total of 1166 JIA cases and 9500 unrelated controls of European ancestry. Correlation of SNP genotype and gene expression was investigated. Then we conducted targeted resequencing of a candidate locus, among a subset of 480 cases and 480 controls. SUM test was performed to evaluate the association of the identified rare functional variants.

Results

The CXCR4 locus on 2q22.1 was found to be significantly associated with JIA, peaking at SNP rs953387. However, this result is subjected to subpopulation stratification within the subjects of European ancestry. After adjusting for principal components, nominal significant association remained (p < 10−4). Because of its interesting known function in immune regulation, we carried out further analyses to assess its relationship with JIA. Expression of CXCR4 was correlated with CXCR4 rs953387 genotypes in lymphoblastoid cell lines (p = 0.014) and T-cells (p = 0.0054). In addition, rare non-synonymous and stop-gain sequence variants in CXCR4, putatively damaging for CXCR4 function, were significantly enriched in JIA cases (p = 0.015).

Conclusion

Our results suggest the association of CXCR4 variants with JIA, implicating that this gene may be involved in the pathogenesis of autoimmune disease. However, because this locus is subjected to population stratification within the subjects of European ancestry, additional replication is still necessary for this locus to be considered a true risk locus for JIA. This cell-surface chemokine receptor has already been targeted in other diseases and may serve as a tractable therapeutic target for a specific subset of pediatric arthritis patients with additional replication and functional validation of the locus.

Keywords

Juvenile idiopathic arthritisGenome-wide association studyCXCR4Targeted resequencing

Background

Pediatric arthritis is the leading cause of acquired disability in children, afflicting about one in 1000 children worldwide [1, 2], all ethnicities and both genders, with onset as early as the first year of life. Classification schemes for pediatric arthritis are under evolution, akin to the recent classification changes for adult rheumatoid arthritis [3]; juvenile rheumatoid arthritis (JRA) is the term used historically in North America, while juvenile idiopathic arthritis (JIA) is the preferred name elsewhere, and is now used increasingly worldwide. JIA is defined as a group of chronic arthritides of unknown etiology, occurring in children from 0 to 16 years of age [4]. Morbidity associated with JIA can be life-long – with as many as 50 % of children with JIA entering adulthood with active disease [1, 2] – and represents a significant medical, financial, and emotional burden for patients, their families, and society. In the United States alone, arthritis and rheumatic diseases impact more than 46 million adults and 300,000 children, at a cost of $128 billion annually in direct and indirect medical costs [57]. Adults with JIA have lower rates of employment than matched controls, and health-related quality of life is diminished in adults with JIA, particularly in those with active disease [8]. Prompt recognition of the disease is important in preventing permanent disability; however, lack of specific confirmatory testing often delays diagnosis. The optimal management of JIA remains complicated and poorly defined, despite recent advances in therapy [1, 2].

The etiology of JIA is largely unknown. To our knowledge, there are no data supporting a major role for environmental exposures [9]. This does not preclude a role of the environment in the pathogenesis of JIA, but research to identify environmental risk factors is lacking. On the other hand, strong contribution of genetic components has been implicated from twin to family studies [10]: monozygotic twins have a concordance rate between 25 and 40 %; the calculated sibling recurrence risk ratio (λs = 15–30) is similar to that calculated for type 1 diabetes. Sibling pairs tend to show concordance for age of onset, subtype and course; and a subset of patients with JIA exhibits a heritable predisposition to develop this disease with an autosomal dominant pattern of inheritance.

Yet, in comparison to other autoimmune diseases of similar prevalence, the genetic etiology of JIA remains largely elusive. The major histocompatibility complex (MHC), in particular, the HLA-DRB1 locus, has been established as having the strongest influence on susceptibility to JIA [11], contributing ~20 % of the proportion of sibling recurrent risk [12]. Non-MHC loci are important as well, with 16 loci now associated with JIA at genome-wide significance. Fourteen of these were identified for the first time by a recent Immunochip analysis [13], a hypothesis-driven approach that focused upon genes with known associations with immune disorders [14]. To comprehensively search for genes related to JIA and given that the pathophysiological mechanisms underlying JIA are unknown, we took an unbiased approach of genome-wide association study (GWAS) and performed replication studies in independent cohorts, including a total of 1166 cases and 9500 controls after quality control (QC) filtering. We subsequently performed targeted resequencing at identified candidate locus of CXCR4 gene among a subset of 480 cases and 490 controls. Here we report that variants in gene CXCR4 associate with JIA.

Methods

Participants

The JIA cases in our study were recruited from five sites in USA, Australia, and Norway: Texas Scottish Rite Hospital for Children (TSRHC; Dallas, Texas), Children’s Mercy Hospitals and Clinics (CMHC; Kansas City, Missouri), the Children's Hospital of Philadelphia (CHOP; Philadelphia, Pennsylvania), the Murdoch Childrens Research Institute (MCRI; Royal Children’s Hospital, Melbourne, Australia), and Oslo University Hospital (OUH; Oslo, Norway). (Table 1, Additional file 1: Table S1). A subset of subjects from these sites has been described previously [1519]. JIA diagnosis was made according to the International League of Associations for Rheumatology (ILAR) revised criteria [4] and confirmed using the JIA CalculatorTM software (URLs) [20], an algorithm-based tool adapted from the ILAR criteria. All JIA cases were of age of onset <16 years old.
Table 1

Demographic and clinical characteristics of our JIA dataset

JIA SubtypesA

% female

Age (years)B

Oligoarthritis, persistent

73 %

5.9 (2.9,9.7)

Oligoarthritis, extended

82 %

3.95 (2.4,7.8)

Polyarthritis, RF negative

79 %

7.48 (3.2,11.3)

Polyarthritis, RF positive

95 %

13.5 (10.3,15.1)

Systemic arthritis

67 %

6.6 (3.2,11.1)

Enthesitis-related arthritis

40 %

11.9 (9.0,14.1)

Psoriatic arthritis

71 %

9.9 (7.0,13.2)

Undifferentiated arthritis

55 %

9.8 (4.5,13.8)

Total

68 %

8.3 (3.8,12.2)

ARevised ILAR criteria.

BAge (years): median (25 % percentile, 75 % percentile)

The clinical data of JIA case in the CHOP cohort were collected from the JIA Registry maintained within the CHOP Division of Rheumatology; clinical data of case samples from TSRHC, CMHC, MCRI, and OUH were drawn from medical records provided by the respective sites and stored in a de-identified database at the Center for Applied Genomics of the CHOP Research Institute.

The control subjects used are unrelated and disease-free children recruited within the CHOP Healthcare Network. Control subjects had no history of JIA or other chronic illnesses and were screened as negative for a diagnosis of autoimmune diseases, based on data from CHOP’s electronic health record and by intake questionnaires obtained by the recruiting staff from the Center for Applied Genomics. A total of 6500 pediatric controls passed stringent quality control (QC) filtering, as detailed below; post-QC, cases and controls were matched based on the multidimensional scaling (MDS) analysis [21, 22]. For OUH cohort, the 3000 well-characterized subjects from the Wellcome Trust Case–control Consortium (WTCCC) [21] were used as controls.

We combined TSRHC and CMHC samples to form the discovery cohort, and kept CHOP, MCRI and OUH cohorts as three independent replication cohorts.

Ethics statement

The study was approved by the institutional review boards of TSRHC, CMHC, CHOP, MCRI, OUH, and CCHMC, and was compliant with HIPAA regulations. Parental written informed consent was obtained from all participants prior to inclusion in this study for the purpose of DNA collection and genotyping.

Genotyping

All samples except those in the OUH replication cohort were genotyped using Illumina HumanHap550 BeadChip or the Human610-Quad arrays. The 530,000 SNPs that are overlapped by these two platforms were included in the study. Samples in the OUH replication cohort were genotyped using the Affymetrix GeneChip 500 K Mapping Array Set.

Quality control

We employed the MDS algorithm implemented in PLINK to infer population structure, with the 924 individuals from the HapMap project as reference. Only samples of genetically inferred European ancestry were kept for further analysis. We then applied QC filters to exclude samples of poor genotyping quality prior to association analysis. A sample was excluded if the genotype call rate was <95 % or if the sample showed excess or deficient heterozygosity (inbreeding coefficient |F| > 0.1). Cryptic relatedness or erroneous duplicates were evaluated using pair-wise identity-by-descent estimation, and the sample with lower genotype call rate was removed from each identified relative pair. In our study, we also eliminated SNPs with genotype call rate <98 %, with minor allele frequency (MAF) <1 % in either cases or controls, or if there was significant departure from Hardy-Weinberg equilibrium (p < 0.0001). In the discovery cohort, a total of 518,907 genotyped SNPs passed QC and were included in analysis.

Principal component analysis (PCA)

After the above sample and SNP QC, we conducted principal component analysis, trying to resolve relationship within-European samples. Using PLINK, we performed LD pruning and SNP exclusion so that only independent SNPs (r2 < 0.2) on the autosomes were kept for PCA. We then performed PCA using EIGENSTRAT [23]. MDS analysis was also performed with the independent SNPs using PLINK.

Association analyses

For genotyped SNPs, association was tested by basic allelic test (chi-square test) and the odds ratio was calculated with respect to the minor allele using PLINK [22]. Logistic regression analyses were additionally performed, including the first 10 coordinates from the MDS analysis as covariates. Similar analyses were also performed including the first 10 principal components from the PCA analysis as covariates. Conditional association analysis was performed by including the genotype of the most associated SNP rs953387 as a covariate.

Imputation

Imputation was carried out using software MACH 1.0 [24], with the reference panel of the HapMap CEU samples (HapMap release 22, NCBI build 36). The default two-step procedure was adopted for imputation. Imputed SNPs with MAF <0.01 in either cases or controls and SNPs with poor imputation quality (r2 < 0.3) were excluded from further analysis. We also zeroed out imputed genotypes with a posterior probability of <0.9.

Meta-analysis

We performed meta-analysis using the inverse variance based method implemented in software METAL [25], which accounts for the direction of association relative to a consistent reference allele and adopts a fixed effect model. In this method, the effect size estimate of each cohort is weighted by its corresponding standard error. All meta-analyses comply with MOOSE guidelines (URLs).

Targeted resequencing

We selected 480 patients with JIA and 480 controls without history of any autoimmune or inflammatory diseases, all of European ancestry based on the above MDS analysis. Samples were pooled in batches of 8 cases or 8 controls. One control pool was excluded for final analysis because it failed QC. Library preparation for targeted resequencing was performed according to the TruSeq (Illumina) sample-preparation protocol. DNA libraries were then hybridized to customized probes for capturing CXCR4 with NimbleGen SeqCap EZ Choice Library (Roche NimbleGen). The captured region is chr2:136871907–136895725, including introns. CXCR4-enriched libraries were sequenced on the HiSeq 2000 (Illumina).

We performed sequence alignment using BWA against the reference human genome (UCSC hg19). We achieved ~320X coverage per pool or ~40X per individual. We performed variant calling using SNVer [26], a statistical tool designed for pooled sequencing data. We used ANNOVAR software [27] to annotate variants. Each pool has 2 × 8 = 16 haplotypes, so we estimated allele frequency by rounding X/K*16, where X is the number of reads carrying the alternative allele, and K is the total coverage.

Statistical analysis for targeted sequencing

For the sequencing data, we employed the SUM test [28] for testing the association of the identified multiple non-synonymous variants. We computed the SUM association p value using the R package AssotesteR. Specifically, we used a permutation version of SUM, in order to prevent an inflated Type I error.

Sanger sequencing

We performed Sanger sequencing to validate the rare non-synonymous and stop-gain sequence variants identified by targeted resequencing. Primers for all the five variants were designed using software Primer3 [29, 30] (URLs). Purification of PCR products was conducted using ExoSAP-it (USB, Affymetrix), and Sanger sequencing on both strands was performed using Big Dye Terminator Cycle Sequencing Kit v3.1 Kit (Applied Biosystems) with ABI 3130xl Genetic Analyzer (Applied Biosystems).

eQTL analyses

To test association between SNP genotypes and gene expression quantified in immortalized B-lymphocytes and T-cells, we performed in silico analysis using publicly available data from genome-wide expression analysis of quantitative trait loci (eQTL) of the 270 individuals genotyped in the HapMap Project (including 30 Caucasian trios of Northern and Western European origin [CEU]) [3134] and the 85 individuals of the GenCord project (a collection of cell lines from umbilical cords of individuals of Western European origin) [35]. Linear regression was used to test the association between gene expression and SNP genotypes under additive model [32]. SNP genotype was coded as 0, 1, and 2, corresponding to the counts of the minor allele in each genotype.

Results

Replication of known JIA susceptibility loci

We performed a genome-wide association study in the discovery cohort (TSRHC + CMHC) including 388 children with JIA and 2500 genetically matched controls of European ancestry with high-quality SNP array data (Table 1, Additional file 1: Table S1). Then three independent JIA cohorts (CHOP, MCRI, OUH) were analyzed for replication and followed by meta-analysis of all the cohorts in a total of 1166 cases and 9500 controls (Table 1, Additional file 1: Table S1). The age at onset, gender, and subtype distributions of all case cohorts are similar to those reported previously for JIA [1].

We focused on the phenotypic commonality amongst our patients, that is, chronic inflammation of the joints. We observed a strong genome-wide significant association at the HLA locus on 6p21 (Additional file 1: Table S2, Additional file 1: Figure S1), A total of 24 SNPs surpassed genome-wide significance threshold at this region in the discovery cohort. Furthermore, three loci which previously have been implicated in JIA and several other autoimmune diseases [10, 36, 37] – the PTPN22 locus on 1p13, the IL2RA locus on 10p15, and the ANTXR2 locus on 4q21.21 – were nominally associated with JIA (Additional file 1: Table S3). Replication of these known JIA susceptibility loci demonstrated the validity of our study.

Novel association of CXCR4 common variants

In addition to these known loci, we found a novel association signal at 2q22.1, with the most significant marker being rs953387 (p = 2.07 × 10−10; OR 0.59, 95 % CI 0.50–0.69). Six genotyped SNPs and ten additional imputed SNPs located on 2q22.1 of p value < 5 × 10−8 (Additional file 1: Table S4–S5, Additional file 1: Figure S1–S2) in the discovery cohort. Conditional on the top SNP rs953387, the significant association of the other SNPs were ablated, suggesting a single association signal at this locus. These SNPs were all nominally significant in each of our three independent replication cohorts. (Additional file 1: Table S4). Combined meta-analysis of all four cohorts indicated that four SNPs at the 2q22.1 locus were of p values < 5 × 10−8 (Additional file 1: Table S4).

However, as CXCR4 is near a known stratified locus (nearby the lactase gene) [38], logistic regression analysis including the first ten coordinates from the MDS analysis as covariates brought the locus p value below genome-wide significance (top associated SNP rs1016269, P = 4.70 × 10−5). Similarly, using the first 10 principal components as the covariates in the logistic region association, we obtained similar results (top associated SNP rs1016269, P = 2.80 × 10−5). Thus, our original association results were inflated due to subpopulation stratification within the subjects of European ancestry. The association of CXCR4 was nominally significant with the best p-value <0.0001. When we evaluated the association by another method, permutation tests with the inclusion of the first ten coordinates from the MDS analysis as covariates in each association analysis, we obtained similar results of nominally significant results based on 10,000 permutations. CXCR4 is an interesting gene because of its known role in immune regulation in a variety of immune cell types as a chemokine receptor. Gene CXCR4, is expressed on the surface of T-cells, B-cells, monocytes, neutrophils and dendritic cells (Additional file 1: Figure S3). The important function of CXCR4 during B cell development and activation [39, 40], and the key role of B cells in pathogenesis of JIA [41] make CXCR4 an intriguing target worth of further examination. Because of sub-population stratification, additional replication is still necessary for this locus to be considered a true risk locus for JIA. Its association with JIA need to be further investigated by stratified analysis in more refined homogeneous sub-populations of European ancestry, with a larger sample size. Further functional studies would also be required to demonstrate its potential contribution to JIA etiology.

Correlation between SNP genotype and CXCR4 expression

Additionally, rs953387 was significantly associated with the mRNA levels of CXCR4 (p = 0.014; Additional file 1: Figure S4) among HapMap dataset of 30 CEU children in the Sanger Institute GENe Expression VARiation (Genevar) public database (URLs), which profiles gene expression in immortalized B-lymphocyte samples [31]. Analysis of an independent dataset of T-cell lines from umbilical cords of 75 individuals of Western European origin [35] also demonstrated association between genotypes of another significant SNP rs1016269 at CXCR4 locus (Additional file 1: Table S5) and levels of CXCR4 expression (p = 0.0054; Additional file 1: Figure S3). These data suggest that common variants at CXCR4 locus may regulate mRNA expression of this chemokine receptor.

Novel association of CXCR4 rare variants

In addition to common variants, rare variants also contribute to disease susceptibity and usually confer a larger effect than common variants. We further examined rare variants at this locus by conducting deep resequencing in 480 JIA cases and 480 controls. Table 2 shows the variants identified in the coding region of CXCR4. Of interest are 4 non-synonymous and 1 stop-gain SNVs. These are all rare variants that are not catalogued in current variant databases (1000G and ESP6500) or with an extreme low frequency (0.0003). Four of these five rare variants are present only in JIA patients, not in controls. The SUM test produced a significance p value of 0.015 when testing the association of these 5 variants, suggesting that rare variants in the CXCR4 gene may be contributing to the pathogenesis of JIA.
Table 2

Summary of variants in CXCR4 coding-region by deep resequencing

Chr

Pos

Ref

Obs

Exonic Function

ESP6500

1000G

dbSNP135

CASE Freq.

CTRL Freq.

chr2

136872553

G

A

synonymous SNV

0.000461

0.0014

rs144110709

0

1

chr2

136872565

G

C

synonymous SNV

   

0

1

chr2

136872705

T

C

nonsynonymous SNV

   

0

1

chr2

136872715

G

A

synonymous SNV

0.003306

0.0018

rs148279552

3

7

chr2

136872727

A

G

synonymous SNV

0.000077

 

rs146627075

1

0

chr2

136872970

G

T

nonsynonymous SNV

   

1

0

chr2

136873084

G

A

synonymous SNV

0.036983

0.06

rs2228014

40

41

chr2

136873341

T

G

nonsynonymous SNV

0.000308

 

rs56400844

2

0

chr2

136873491

G

C

nonsynonymous SNV

   

1

0

chr2

136873496

A

T

stopgain SNV

   

1

0

Chr chromosome, Pos position on human genome build hg19, Ref reference allele, Obs the variant allele observed in our JIA dataset, ESP6500 variant allele frequency in Exome Sequencing Project, 1000G variant allele frequency in Thousand Genome Project, dbSNP 135 SNP rs ID in Single Nucleotide Polymorphism database of human genome build 135, CASE Freq variant allele frequency among cases, CTRL freq variant allele frequency among controls

Then we performed Sanger sequencing to validate their genotype status. The primer sequences for each rare variant are shown in Additional file 1: Table S6. Among 40 samples of the 5 pools from which the rare variants were detected, 33 samples were left with enough DNA for Sanger sequencing. No genomic DNA was left for 4 samples in pool from which variant chr2:136872970 was identified and 3 samples in pool from which variant chr2: 136873341 was found. Among the 33 samples with enough genomic DNA, 4 samples were found carrying the rare variant identified in deep sequencing (Fig. 1).
Fig. 1

Sanger validation of rare variants in gene CXCR4. The sequencing chromatograms are shown for the sample carrying the rare variant allele and a representative control that does not have the rare variant allele. a chr2:136872705; b chr2:136873341; c chr2:136873491; d chr2:136873496. The rare variants are highlighted in the figure

Discussion

In a combined sample set of more than 1100 JIA subjects of European ancestry, we replicated common genetic variants at loci of HLA, PTPN22, IL2RA and ANTXR2 that have been reported for association with susceptibility to JIA. We also found a nominally significant association at CXCR4 which has been implicated in immune regulation, demonstrated the correlation between CXCR4 variants genotype and its gene expression level. We further showed that rare non-synonymous and stop-gain variants in CXCR4 are enriched in JIA cases. Our data support a role for altered expression of CXCR4 in JIA pathogenesis, and present the first genetic demonstration of a potential role for the chemokine receptor, CXCR4, in the pathogenesis of autoimmune disease. Because this locus is subjected to population stratification within the subjects of European ancestry, additional replication is still necessary for this locus to be considered a true risk locus for JIA.

Few genetic studies of JIA have been carried out at genome-wide scale. Previously reported GWASs of JIA were all limited by small size [42, 43]. A more recent study using Immunochip, took a hypothesis-driven approach, targeting immune-specific genes. Several significant new loci were identified from the study [13], however the Immunochip does not capture variants across a large proportion of the genome. Our study was composed of a large dataset with comprehensive genome SNP coverage, and the candidate gene identified was examined using targeted resequencing with a large number of samples and high coverage.

Chemokine receptors impact immune system development and function in part via regulation of cell migration. The G protein-coupled chemokine receptor, CXCR4, is expressed on the surface of T-cells, B-cells, monocytes, neutrophils and dendritic cells (Additional file 1: Figure S3), and is activated exclusively by CXCL12 (also known as stromal-derived-factor-1, SDF-1), a small peptide mediator and potent chemoattractant for leukocytes, including B- and T-cells. CXCR4 and its ligand, CXCL12, have been shown to play a role in B-cell production, myelopoiesis, integrin activation, angiogenesis, and chemotaxis [25]. Intriguingly, the human immunodeficiency virus (HIV-1) has usurped CXCR4’s unique CXCL12 binding site, exploiting CXCR4 as a co-receptor in later stages of HIV-1 infection, and CXCR4 antagonists have been explored as treatments for HIV infection. Binding of CXCR4 to CXCL12 is also proposed to play a role in cancer metastases, and CXCR4 antagonists are under study in human clinical trials for solid and non-solid tumors [44]. Available therapeutic agents targeting the CXCR4-CXCL12 axis for activation or inhibition include plerixafor (AMD3100), recombinant CXCL12, and high-affinity CXCR4 and CXCL12 monoclonal antibodies, some of which are already in use in the clinic but not approved for use in children. The recent report of crystal structures of CXCR4 with small-molecule and cyclic peptide inhibitors [45] provide new opportunities for drug discovery efforts targeting this receptor.

CXCR4 and CXCL12 have been implicated in the pathogenesis of autoimmune diseases [44, 46]. In mouse models of autoimmune disease, modulation of CXCR4 alters trafficking of leukocytes to peripheral organs and polarization of regulatory T cells, and accelerates onset of disease [47, 48]. This is consistent with our data showing that a risk variant of CXCR4 correlates with decreased expression of CXCR4. An alternate hypothesis is that the effect of low CXCR4 expression is indirect and leads to a compensatory increase of the CXCR4 ligand, CXCL12. Our preliminary data suggest that the risk variant of CXCR4 correlates with increased expression of CXCL12 (data not shown). This is consistent with models of collagen-induced arthritis in which CXCL12 acts as a pro-inflammatory factor in the pathogenesis of inflammatory arthritis [49, 50], and with human studies in which CXCL12 enhances cellular proliferation and cytokine expression by peripheral blood T cells, upregulates expression of cytokines and chemokines by fibroblast-like synoviocytes from patients with RA [51], and mediates lymphocyte ingress into RA synovial tissue, synovial neovascularisation, and osteoclastogenesis [52]. Translation of our discovery into therapeutic benefit for a specific group of JIA patients will require additional genetic replication studies, proper functional validation and greater insight into the pathogenic role of CXCR4 in JIA.

Conclusions

We uncovered common SNPs at the CXCR4 locus associated with JIA and further found rare functional variants at CXCR4 enriched in JIA cases. Our results suggest that genetic variants at the CXCR4 locus may predispose to the development of JIA. Because of sub-population stratification, additional replication is still necessary for this locus to be considered a true risk locus for JIA. The extensive literature surrounding the biology of CXCR4 and its binding partner CXCL12 in health and disease, and the ready availability of targeted therapeutic agents make CXCR4 a particularly attractive candidate for further genetic replication and functional investigation of its pathogenic role and therapeutic potential in JIA and other autoimmune diseases affecting children.

Notes

Declarations

Acknowledgments

We gratefully thank all the children with JIA and their families at the participating study sites who were enrolled in this study and all the control subjects who donated blood samples to the Children's Hospital of Philadelphia (CHOP) for genetic research purposes. We thank the technical staff at the Center for Applied Genomics at CHOP for producing the genotypes used for analyses, and the nursing, medical assistant and medical staff for their help with recruitment of patient and control subjects for the study. This study was supported by Institutional Development Funds from The Children´s Hospital of Philadelphia, RC1AR058606 and U01HG006830. The expression work reported in this project was funded in part with federal funds from the National Cancer Institute, National Institutes of Health, under contract HHSN26120080001E, and by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Division of Rheumatology, The Children’s Hospital of Philadelphia
(2)
Department of Pediatrics, University of Pennsylvania School of Medicine
(3)
The Center for Applied Genomics, The Children’s Hospital of Philadelphia
(4)
Department of Computer Science, New Jersey Institute of Technology
(5)
Basic Research Laboratory, Center for Cancer Research, National Cancer Institute, Leidos Biomedical Research Inc., Frederick National Laboratory
(6)
Sarah M. and Charles E. Seay Center for Musculoskeletal Research, Texas Scottish Rite Hospital for Children
(7)
Division of Rheumatology, Texas Scottish Rite Hospital
(8)
Division of Rheumatology, Children’s Mercy- Kansas City
(9)
Murdoch Childrens Research Institute
(10)
Paediatric Rheumatology Unit, Royal Children’s Hospital
(11)
Department of Rheumatology, Oslo University Hospital
(12)
Cincinnati Children’s Hospital Medical Center
(13)
Center for Public Health Genomics and Department of Biostatistical Sciences, Wake Forest School of Medicine
(14)
Department of Psychiatry and Behavioral Sciences, UUniversity of Southern California
(15)
Institute of Immunology, Oslo University Hospital
(16)
Department of Paediatrics, University of Melbourne
(17)
Division of Human Genetics, The Children’s Hospital of Philadelphia
(18)
Present Address: Department of Pediatrics, Nemours Research Institute, Nemours Children’s Hospital

References

  1. Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007;369(9563):767–78.Google Scholar
  2. Prakken B, Albani S, Martini A. Juvenile idiopathic arthritis. Lancet. 2011;377(9783):2138–49.View ArticlePubMedGoogle Scholar
  3. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569–81.View ArticlePubMedGoogle Scholar
  4. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, He X, Maldonado-Cocco J, Orozco-Alcala J, Prieur A-M. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390–2.PubMedGoogle Scholar
  5. Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, Liang MH, Kremers HM, Mayes MD, Merkel PA. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum. 2008;58(1):15–25.View ArticlePubMedGoogle Scholar
  6. Yelin E, Murphy L, Cisternas MG, Foreman AJ, Pasta DJ, Helmick CG. Medical care expenditures and earnings losses among persons with arthritis and other rheumatic conditions in 2003, and comparisons with 1997. Arthritis Rheum. 2007;56(5):1397–407.View ArticlePubMedPubMed CentralGoogle Scholar
  7. Centers for Disease C, Prevention. National and state medical expenditures and lost earnings attributable to arthritis and other rheumatic conditions--United States. MMWR Morbidity and mortality weekly report 2007. 2003;56(1):4–7.Google Scholar
  8. Foster HE, Marshall N, Myers A, Dunkley P, Griffiths ID. Outcome in adults with juvenile idiopathic arthritis: a quality of life study. Arthritis Rheum. 2003;48(3):767–75.View ArticlePubMedGoogle Scholar
  9. Ellis JA, Munro JE, Ponsonby A-L. Possible environmental determinants of juvenile idiopathic arthritis. Rheumatology (Oxford). 2010;49(3):411–25.View ArticleGoogle Scholar
  10. Woo P, Colbert RA. An overview of genetics of paediatric rheumatic diseases. Best Pract Res Clin Rheumatol. 2009;23(5):589–97.View ArticlePubMedPubMed CentralGoogle Scholar
  11. Hollenbach JA, Thompson SD, Bugawan TL, Ryan M, Sudman M, Marion M, Langefeld CD, Thomson G, Erlich HA, Glass DN. Juvenile idiopathic arthritis and HLA class I and class II interactions and age-at-onset effects. Arthritis Rheum. 2010;62(6):1781–91.View ArticlePubMedPubMed CentralGoogle Scholar
  12. Prahalad S, Shear ES, Thompson SD, Giannini EH, Glass DN. Increased prevalence of familial autoimmunity in simplex and multiplex families with juvenile rheumatoid arthritis. Arthritis Rheum. 2002;46(7):1851–6.View ArticlePubMedGoogle Scholar
  13. Hinks A, Cobb J, Marion MC, Prahalad S, Sudman M, Bowes J, Martin P, Comeau ME, Sajuthi S, Andrews R. Dense genotyping of immune-related disease regions identifies 14 new susceptibility loci for juvenile idiopathic arthritis. Nat Genet. 2013;45(6):664–9.View ArticlePubMedPubMed CentralGoogle Scholar
  14. Cortes A, Brown MA. Promise and pitfalls of the Immunochip. Arthritis Res Ther. 2011;13(1):101.View ArticlePubMedPubMed CentralGoogle Scholar
  15. Behrens EM, Finkel TH, Bradfield JP, Kim CE, Linton L, Casalunovo T, Frackelton EC, Santa E, Otieno FG, Glessner JT. Association of the TRAF1-C5 locus on chromosome 9 with juvenile idiopathic arthritis. Arthritis Rheum. 2008;58(7):2206–7.View ArticlePubMedGoogle Scholar
  16. Wise CA, Bennett LB, Pascual V, Gillum JD, Bowcock AM. Localization of a gene for familial recurrent arthritis. Arthritis Rheum. 2000;43(9):2041–5.View ArticlePubMedGoogle Scholar
  17. Becker ML, Gaedigk R, van Haandel L, Thomas B, Lasky A, Hoeltzel M, Dai H, Stobaugh J, Leeder JS. The effect of genotype on methotrexate polyglutamate variability in juvenile idiopathic arthritis and association with drug response. Arthritis Rheum. 2011;63(1):276–85.View ArticlePubMedGoogle Scholar
  18. Eike MC, Nordang GBN, Karlsen TH, Boberg KM, Vatn MH, Dahl-Jørgensen K, Rønningen KS, Joner G, Flatø B, Bergquist A. The FCRL3-169T > C polymorphism is associated with rheumatoid arthritis and shows suggestive evidence of involvement with juvenile idiopathic arthritis in a Scandinavian panel of autoimmune diseases. Ann Rheum Dis. 2008;67(9):1287–91.View ArticlePubMedGoogle Scholar
  19. Ellis JA, Ponsonby A-L, Pezic A, Chavez RA, Allen RC, Akikusa JD, Munro JE. CLARITY - ChiLdhood Arthritis Risk factor Identification sTudY. Pediatric Rheumatology Online J. 2012;10(1):37.View ArticleGoogle Scholar
  20. Behrens EM, Beukelman T, Gallo L, Spangler J, Rosenkranz M, Arkachaisri T, Ayala R, Groh B, Finkel TH, Cron RQ. Evaluation of the presentation of systemic onset juvenile rheumatoid arthritis: data from the Pennsylvania Systemic Onset Juvenile Arthritis Registry (PASOJAR). J Rheumatol. 2008;35(2):343–8.PubMedGoogle Scholar
  21. Wellcome Trust Case Control C. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. 2007;447(7145):661–78.View ArticleGoogle Scholar
  22. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MAR, Bender D, Maller J, Sklar P, Bakker PIW, Daly MJ. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81(3):559–75.Google Scholar
  23. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet. 2006;38(8):904–9.View ArticlePubMedGoogle Scholar
  24. Li Y, Willer C, Sanna S, Abecasis G. Genotype imputation. Annu Rev Genomics Hum Genet. 2009;10:387–406.View ArticlePubMedPubMed CentralGoogle Scholar
  25. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics (Oxford, England). 2010;26(17):2190–1.View ArticleGoogle Scholar
  26. Wei Z, Wang W, Hu P, Lyon GJ, Hakonarson H. SNVer: a statistical tool for variant calling in analysis of pooled or individual next-generation sequencing data. Nucleic Acids Res. 2011;39(19):e132.View ArticlePubMedPubMed CentralGoogle Scholar
  27. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010;38(16):e164.View ArticlePubMedPubMed CentralGoogle Scholar
  28. Pan W. Asymptotic tests of association with multiple SNPs in linkage disequilibrium. Genet Epidemiol. 2009;33(6):497–507.View ArticlePubMedPubMed CentralGoogle Scholar
  29. Koressaar T, Remm M. Enhancements and modifications of primer design program Primer3. Bioinformatics. 2007;23(10):1289–91.View ArticlePubMedGoogle Scholar
  30. Untergasser A, Cutcutache I, Koressaar T, Ye J, Faircloth BC, Remm M, Rozen SG. Primer3--new capabilities and interfaces. Nucleic Acids Res. 2012;40(15):e115.View ArticlePubMedPubMed CentralGoogle Scholar
  31. Yang T-P, Beazley C, Montgomery SB, Dimas AS, Gutierrez-Arcelus M, Stranger BE, Deloukas P, Dermitzakis ET. Genevar: a database and Java application for the analysis and visualization of SNP-gene associations in eQTL studies. Bioinformatics (Oxford, England). 2010;26(19):2474–6.View ArticleGoogle Scholar
  32. Stranger BE, Forrest MS, Clark AG, Minichiello MJ, Deutsch S, Lyle R, Hunt S, Kahl B, Antonarakis SE, Tavaré S. Genome-wide associations of gene expression variation in humans. PLoS Genet. 2005;1(6):e78.View ArticlePubMedPubMed CentralGoogle Scholar
  33. Stranger BE, Forrest MS, Dunning M, Ingle CE, Beazley C, Thorne N, Redon R, Bird CP, Grassi A, Lee C. Relative impact of nucleotide and copy number variation on gene expression phenotypes. Science (New York, NY). 2007;315(5813):848–53.Google Scholar
  34. Stranger BE, Nica AC, Forrest MS, Dimas A, Bird CP, Beazley C, Ingle CE, Dunning M, Flicek P, Koller D. Population genomics of human gene expression. Nat Genet. 2007;39(10):1217–24.View ArticlePubMedPubMed CentralGoogle Scholar
  35. Dimas AS, Deutsch S, Stranger BE, Montgomery SB, Borel C, Attar-Cohen H, Ingle C, Beazley C, Gutierrez Arcelus M, Sekowska M. Common regulatory variation impacts gene expression in a cell type-dependent manner. Science (New York, NY). 2009;325(5945):1246–50.View ArticleGoogle Scholar
  36. Thompson SD, Sudman M, Ramos PS, Marion MC, Ryan M, Tsoras M, Weiler T, Wagner M, Keddache M, Haas JP. The susceptibility loci juvenile idiopathic arthritis shares with other autoimmune diseases extend to PTPN2, COG6, and ANGPT1. Arthritis Rheum. 2010;62(11):3265–76.View ArticlePubMedPubMed CentralGoogle Scholar
  37. Zhernakova A, van Diemen CC, Wijmenga C. Detecting shared pathogenesis from the shared genetics of immune-related diseases. Nat Rev Genet. 2009;10(1):43–55.View ArticlePubMedGoogle Scholar
  38. Campbell CD, Ogburn EL, Lunetta KL, Lyon HN, Freedman ML, Groop LC, Altshuler D, Ardlie KG, Hirschhorn JN. Demonstrating stratification in a European American population. Nat Genet. 2005;37(8):868–72.View ArticlePubMedGoogle Scholar
  39. Ma Q, Jones D, Springer TA. The chemokine receptor CXCR4 is required for the retention of B lineage and granulocytic precursors within the bone marrow microenvironment. Immunity. 1999;10(4):463–71.View ArticlePubMedGoogle Scholar
  40. Nie Y, Waite J, Brewer F, Sunshine MJ, Littman DR, Zou YR. The role of CXCR4 in maintaining peripheral B cell compartments and humoral immunity. J Exp Med. 2004;200(9):1145–56.View ArticlePubMedPubMed CentralGoogle Scholar
  41. Wiegering V, Girschick HJ, Morbach H. B-cell pathology in juvenile idiopathic arthritis. Arthritis. 2010;2010:759868.View ArticlePubMedPubMed CentralGoogle Scholar
  42. Hinks A, Barton A, Shephard N, Eyre S, Bowes J, Cargill M, Wang E, Ke X, Kennedy GC, John S. Identification of a novel susceptibility locus for juvenile idiopathic arthritis by genome-wide association analysis. Arthritis Rheum. 2009;60(1):258–63.View ArticlePubMedPubMed CentralGoogle Scholar
  43. Thompson SD, Marion MC, Sudman M, Ryan M, Tsoras M, Howard TD, Barnes MG, Ramos PS, Thomson W, Hinksl A. Genome-wide association analysis of juvenile idiopathic arthritis identifies a new susceptibility locus at chromosomal region 3q13. Arthritis Rheum. 2012;64(8):2781–91.Google Scholar
  44. Chong BF, Mohan C. Targeting the CXCR4/CXCL12 axis in systemic lupus erythematosus. Expert Opin Ther Targets. 2009;13(10):1147–53.View ArticlePubMedGoogle Scholar
  45. Wu B, Chien EYT, Mol CD, Fenalti G, Liu W, Katritch V, Abagyan R, Brooun A, Wells P, Bi FC. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science (New York, NY). 2010;330(6007):1066–71.View ArticleGoogle Scholar
  46. Koch AE. Chemokines and their receptors in rheumatoid arthritis: future targets? Arthritis Rheum. 2005;52(3):710–21.View ArticlePubMedGoogle Scholar
  47. Aboumrad E, Madec AM, Thivolet C. The CXCR4/CXCL12 (SDF-1) signalling pathway protects non-obese diabetic mouse from autoimmune diabetes. Clin Exp Immunol. 2007;148(3):432–9.View ArticlePubMedPubMed CentralGoogle Scholar
  48. Meiron M, Zohar Y, Anunu R, Wildbaum G, Karin N. CXCL12 (SDF-1alpha) suppresses ongoing experimental autoimmune encephalomyelitis by selecting antigen-specific regulatory T cells. J Exp Med. 2008;205(11):2643–55.View ArticlePubMedPubMed CentralGoogle Scholar
  49. De Klerck B, Geboes L, Hatse S, Kelchtermans H, Meyvis Y, Vermeire K, Bridger G, Billiau A, Schols D, Matthys P. Pro-inflammatory properties of stromal cell-derived factor-1 (CXCL12) in collagen-induced arthritis. Arthritis Res Ther. 2005;7(6):R1208–20.View ArticlePubMedPubMed CentralGoogle Scholar
  50. Bradfield PF, Amft N, Vernon-Wilson E, Exley AE, Parsonage G, Rainger GE, Nash GB, Thomas AMC, Simmons DL, Salmon M. Rheumatoid fibroblast-like synoviocytes overexpress the chemokine stromal cell-derived factor 1 (CXCL12), which supports distinct patterns and rates of CD4+ and CD8+ T cell migration within synovial tissue. Arthritis Rheum. 2003;48(9):2472–82.View ArticlePubMedGoogle Scholar
  51. Nanki T, Nagasaka K, Hayashida K, Saita Y, Miyasaka N. Chemokines regulate IL-6 and IL-8 production by fibroblast-like synoviocytes from patients with rheumatoid arthritis. J Immunol. 2001;167(9):5381–5.View ArticlePubMedGoogle Scholar
  52. Nanki T, Hayashida K, El-Gabalawy HS, Suson S, Shi K, Girschick HJ, Yavuz S, Lipsky PE. Stromal cell-derived factor-1-CXC chemokine receptor 4 interactions play a central role in CD4+ T cell accumulation in rheumatoid arthritis synovium. J Immunol. 2000;165(11):6590–8.View ArticlePubMedGoogle Scholar

Copyright

© Finkel et al. 2016

Advertisement